MRK · News · 20260930N

Product / Drug Pipeline Progress

Merck & Co., Inc. · 2026-09-30 · Importance 34 · Surprise 42

Merck reported positive Phase 2b results for tulisokibart (MK-7240) in patients with moderate to severe hidradenitis suppurativa, a chronic inflammatory skin disease. The MK-7240-012 trial met its primary endpoint, with active treatment regimens outperforming placebo on HiSCR50, and also achieved key secondary endpoints including improvements in patient quality of life. Tulisokibart showed a safety profile comparable to placebo and may advance to late-stage development, while Merck is also evaluating the anti-TL1A antibody in Phase 3 trials for other inflammatory conditions.

Key facts

• Merck & Co., Inc.'s investigational drug tulisokibart met the primary endpoint in its mid-stage (Phase 2b) study in patients with moderate-to-severe hidradenitis suppurativa.
• Merck & Co., Inc. conducted a Phase 2b multicenter, randomized, double-blind, placebo-controlled trial MK-7240-012 evaluating tulisokibart in patients with moderate to severe hidradenitis suppurativa (HS). source
• Merck & Co., Inc. reported that the Phase 2b MK-7240-012 trial met key secondary endpoints and showed improvements in patient quality of life, with a safety profile comparable to placebo. source
• Merck & Co., Inc.'s positive Phase 2b outcome for tulisokibart positions the antibody drug for advancement into late-stage development. source
• Merck & Co., Inc. presented initial results from its Phase 2b MK-7240-012 trial for tulisokibart at the EADV 2026 Congress. source
• Merck & Co., Inc. closed at $145.31 on the latest trading session reported, marking a -2.66% move from the previous day. source